In a groundbreaking discovery that bridges immunology, muscle biology, and rare genetic disorders, researchers have identified a novel macrophage subset dubbed “Mrep” that orchestrates skeletal muscle regeneration but, paradoxically, also induces pathological bone formation in the devastating condition known as Fibrodysplasia Ossificans Progressiva (FOP). This dual functionality opens new therapeutic avenues both for enhancing muscle repair and for combating heterotopic ossification, a hallmark of FOP. The study, recently published in the Journal of Clinical Investigation, elucidates the sophisticated cellular and molecular mechanisms by which Mrep-derived activin A modulates muscle satellite cells during repair and aberrantly activates mutant ACVR1 receptors in FOP, thereby driving ectopic bone formation.
Skeletal muscle, accounting for nearly half of human body mass and serving as a key driver of locomotion and metabolic regulation, encounters injury routinely due to daily activities or trauma. Regeneration of this tissue is a tightly coordinated biological process involving inflammation and the precise interaction of immune cells and muscle-residing stem cells known as satellite cells. Among immune cells, macrophages are predominant during muscle repair, yet their heterogeneity and specialized functions had remained only partially characterized. The identification of Mrep macrophages, distinguished by surface markers CD9, podoplanin (PDPN), and interleukin-7 receptor (IL-7R), as pivotal activin A producers reveals a previously unappreciated layer within the immune-mediated muscle regeneration framework.
Activin A, a member of the TGF-β superfamily, emerged as a central cytokine secreted by Mrep macrophages. By engaging muscle satellite cells, activin A promotes their proliferation and expedites effective tissue regeneration. This paracrine signaling axis proves vital; mouse models deficient in macrophages or engineered to inhibit activin A secretion exhibited delayed muscle healing. Remarkably, transplantation of purified Mrep cells into these models restored repair capacity, confirming the indispensable role of this macrophage subset. The induction of activin A production by Mrep is tightly regulated through recognition of damage-associated molecular patterns (DAMPs) via Toll-like receptor 4 (TLR4) signaling pathways, linking innate immune sensing of injury to regenerative output.
The research team extended their findings into the pathological context of FOP, a devastating genetic disorder characterized by heterotopic ossification, where traumatically injured muscle and connective tissues progressively ossify, severely impairing mobility and quality of life. The root cause in FOP involves gain-of-function mutations in ACVR1, a receptor for BMP signaling. Intriguingly, activin A, which under normal conditions does not robustly signal through ACVR1, aberrantly activates the mutant receptor variant, instigating osteogenic differentiation of resident mesenchymal progenitor cells. This pathological hijacking of a physiological regeneration pathway by Mrep-secreted activin A delineates a cellular mechanism explaining flare-ups of heterotopic ossification following injury in FOP patients.
Using genetically engineered mouse models mimicking human FOP mutations, the investigators demonstrated that muscle injury provokes robust accumulation of Mrep macrophages at lesion sites, accompanied by elevated activin A levels. This milieu triggers the mutant ACVR1 receptor, precipitating ectopic bone growth within muscle tissue. Strikingly, interventions that either genetically ablated activin A production in macrophages or pharmacologically inhibited TLR4 signaling substantially suppressed heterotopic ossification, underscoring Mrep-derived activin A’s causal role and positioning these pathways as promising therapeutic targets.
Beyond revealing the molecular players, this study reframes our understanding of macrophage plasticity: the very cells that under normal physiological conditions foster regeneration, can become agents of pathology in genetically predisposed environments. The dualistic role of Mrep macrophages exemplifies the complex interplay where inflammation, immune cell function, and developmental signaling converge to impact tissue homeostasis and disease.
Therapeutically, these insights herald a new era. Targeting Mrep macrophage recruitment or function, modulating activin A signaling, or blocking upstream danger signal recognition via TLR4 inhibition offers multiple intervention points. Such strategies provide hope for addressing currently untreatable conditions like FOP while also informing muscle repair enhancement therapies that could benefit a broad spectrum of musculoskeletal disorders, including age-related sarcopenia and trauma.
The implications extend to the broader field of regenerative medicine, where the immune system’s role is increasingly recognized as central—not just in defense, but in guiding tissue restoration or pathology. By dissecting the precise molecular dialogue initiated by Mrep cells, this research provides a blueprint for harnessing macrophage subsets to fine-tune regenerative outcomes or prevent maladaptive responses.
These findings represent a collaborative triumph involving Kanazawa University’s Cancer Research Institute and multidisciplinary scientists, leveraging cutting-edge single-cell RNA sequencing, sophisticated mouse models, and integrative immunological and molecular biology approaches. Such comprehensive methodological synergy was critical to identifying cell-surface markers and functional characteristics that define Mrep and elucidate its secretome and signaling impact.
Future research will no doubt probe the kinetics and spatial dynamics of Mrep infiltration, the spectrum of signals modulating its activation state, and its interplay with other immune and stromal cells in the regeneration microenvironment. Additionally, unraveling how systemic factors such as aging, metabolic status, or comorbidities influence Mrep function might refine therapeutic targeting, broadening benefits beyond rare genetic diseases.
In conclusion, the discovery of Mrep macrophages as critical regulators of muscle repair and pathological ossification reveals a compelling target for next-generation therapies. By modulating this macrophage subset or its secreted activin A, researchers may simultaneously promote healthy muscle regeneration while preventing destructive ectopic bone formation, offering new hope for patients suffering from FOP and other musculoskeletal maladies.
Subject of Research: Muscle regeneration, macrophage subsets, activin A signaling, heterotopic ossification, Fibrodysplasia Ossificans Progressiva (FOP)
Article Title: Activin A secretion by muscle-repairing macrophages induces heterotopic ossification in mice
News Publication Date: 2-Mar-2026
Web References:
http://dx.doi.org/10.1172/JCI193797
Image Credits: Kazuo Okamoto (Kanazawa University)
Keywords: Muscle regeneration, macrophages, activin A, heterotopic ossification, Fibrodysplasia Ossificans Progressiva, ACVR1 mutation, TLR4 signaling, muscle satellite cells, Mrep macrophages, innate immunity, tissue repair, osteogenesis
Tags: activin A role in muscle repairACVR1 receptor mutation effectsFibrodysplasia Ossificans Progressiva pathologyheterotopic ossification mechanismsimmune system in muscle healingmacrophage heterogeneity in tissue repairmolecular pathways of muscle regenerationmuscle regeneration immune cellsmuscle repair and pathological ossificationnovel macrophage subset Mrepskeletal muscle satellite cell regulationtherapeutic targets for FOP
